SARS-CoV-2 antibody concentrations predict COVID-19 vaccine effectiveness, with higher levels correlating with greater protection, according to an ongoing US phase 3 clinical trial yesterday in Science.
A team led by researchers from Fred Hutchinson Cancer Research Center in Seattle evaluated 30,420 adult recipients of the Moderna mRNA COVID-19 vaccine at 99 centers for neutralizing and binding antibodies as correlates of risk for, and protection against, infection.
Problem, Solution, SitRep, or ?:
Recent Comments